GlassScriptPhysician profile
Jing Yuan
NPI 1245693597
$1,458.82
in general payments reported to CMS, 2019-2025
21 companies · $426 in 2025
The $426 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $42.79 · 2021: $121 · 2022: $25.84 · 2023: $391 · 2024: $451 · 2025: $426.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,269.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,268.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $308.21 | 2023 | Xarelto |
| Abbvie INC. | $191.31 | 2023-2025 | Ubrelvy, Qulipta |
| Ethicon INC. | $121.32 | 2021 | |
| Edwards Lifesciences Corporation | $119.76 | 2024 | |
| Pfizer INC. | $101.87 | 2019-2025 | |
| Shield Therapeutics INC | $86.82 | 2023-2025 | Accrufer |
| Novo Nordisk INC | $73.76 | 2023-2025 | Rybelsus, Ozempic |
| Lilly USA, LLC | $54.89 | 2024-2025 | Jardiance, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $51.60 | 2025 | |
| Sumitomo Pharma America, INC. | $48.81 | 2024-2025 | Gemtesa |
| Dexcom, INC. | $46.02 | 2024 | Dexcom G6 Transmitter |
| Idorsia Pharmaceuticals US INC | $34.85 | 2024-2025 | Quviviq, Quviviq |
| Otsuka America Pharmaceutical, INC. | $32.42 | 2025 | Rexulti |
| Medline Industries LP | $30.17 | 2024 | Medline Industries, INC. |
| Astrazeneca Pharmaceuticals LP | $28.65 | 2024 | Farxiga |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $25.90 | 2024 | Givlaari |
| Ultragenyx Pharmaceutical INC. | $25.84 | 2022 | |
| Calliditas Therapeutics US INC. | $22.99 | 2025 | Tarpeyo |
| Insmed, INC. | $22.73 | 2019 | |
| Glaxosmithkline, LLC. | $16.58 | 2024 | Arexvy |
| Exact Sciences Corporation | $14.32 | 2025 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jing Yuan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.